What does PHARM-OZ do?

PHARM-OZ is a pharmacy in Charleroi. Public Limited, started on 1 January 1968, 1 establishment.

What is the address of PHARM-OZ?

The registered office of PHARM-OZ is located at Chaussée de Châtelet 40, 6060 Charleroi.

Is PHARM-OZ still active?

Yes. According to the CBE (30 October 2026) PHARM-OZ is active, legal situation “Normale toestand”, started on 1 January 1968.

Is PHARM-OZ registered on Peppol?

Yes, PHARM-OZ is registered on the Peppol network with ID 0208:0401670169.

What is the enterprise number of PHARM-OZ?

The enterprise number of PHARM-OZ is BE0401670169.

When was PHARM-OZ founded?

PHARM-OZ was founded on 1 January 1968.

Who are the directors of PHARM-OZ?

According to the 2025 annual accounts, the directors of PHARM-OZ are: DERYA GEDERET, PHARMA OZ SRL.

Is PHARM-OZ a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 January 1968; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARM-OZ make in 2025?

PHARM-OZ posted a profit after taxes of € 85,650 in financial year 2025.

What is the revenue of PHARM-OZ?

As a small company, PHARM-OZ is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 310,663.

How much does an employee at PHARM-OZ earn?

The average wage cost per full-time employee at PHARM-OZ was € 58,300 in 2025: staff costs of € 134,144 for 2.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARM-OZ have?

According to the 2025 annual accounts, PHARM-OZ has 2.3 full-time equivalents (FTE).

PHARM-OZ (Public Limited) - Charleroi - BE0401670169

Dossier PHARM-OZ, printed on 30 October 2026 from databakkes.be/en/0401670169/pharm-oz. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARM-OZ from Charleroi, company number BE0401670169, closed financial year 2025 with a result of € 85,650 after tax. For that financial year PHARM-OZ recorded a gross margin of € 310,663 and equity of € 342,955. Compared with financial year 2024, the result moved from € 105,313 to € 85,650. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.

What it is worth Growing

€ 342,955

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 85,650

▼ 19% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 88,838

▼ 34% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 75,000 paid out

88 % of the profit went to the shareholders, mostly to PHARMA OZ (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

2.3

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 134,144

▼ 3% vs 2024

€ 58,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 28,770

▼ 63% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 60,244

▼ 25% vs 2024

€ 19,089 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 175,080

▲ 51% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 26,776

▼ 27% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 205,950 Gross margin 2022: € 205,950 First fiscal year in the series	€ 272,492 Gross margin 2023: € 272,492 ▲ 32% vs 2022 (€ 205,950) Favourable step	€ 316,185 Gross margin 2024: € 316,185 ▲ 16% vs 2023 (€ 272,492) Favourable step	€ 310,663 Gross margin 2025: € 310,663 ▼ 2% vs 2024 (€ 316,185) Unfavourable step	▼ 2%
Profit after taxes	€ 707 Profit after taxes 2022: € 707 First fiscal year in the series	€ 89,261 Profit after taxes 2023: € 89,261 ▲ € 88,553 vs 2022 (€ 707) Favourable step	€ 105,313 Profit after taxes 2024: € 105,313 ▲ 18% vs 2023 (€ 89,261) Favourable step	€ 85,650 Profit after taxes 2025: € 85,650 ▼ 19% vs 2024 (€ 105,313) Unfavourable step	▼ 19%
Equity	€ 262,732 Equity 2022: € 262,732 First fiscal year in the series	€ 301,992 Equity 2023: € 301,992 ▲ 15% vs 2022 (€ 262,732) Favourable step	€ 332,305 Equity 2024: € 332,305 ▲ 10% vs 2023 (€ 301,992) Favourable step	€ 342,955 Equity 2025: € 342,955 ▲ 3% vs 2024 (€ 332,305) Favourable step	▲ 3%
Total debts	€ 173,946 Total debts 2022: € 173,946 First fiscal year in the series	€ 223,677 Total debts 2023: € 223,677 ▲ 29% vs 2022 (€ 173,946) Unfavourable step	€ 326,729 Total debts 2024: € 326,729 ▲ 46% vs 2023 (€ 223,677) Unfavourable step	€ 338,630 Total debts 2025: € 338,630 ▲ 4% vs 2024 (€ 326,729) Unfavourable step	▲ 4%
Cash	€ 103,479 Cash 2022: € 103,479 First fiscal year in the series	€ 82,666 Cash 2023: € 82,666 ▼ 20% vs 2022 (€ 103,479) Unfavourable step	€ 133,765 Cash 2024: € 133,765 ▲ 62% vs 2023 (€ 82,666) Favourable step	€ 88,838 Cash 2025: € 88,838 ▼ 34% vs 2024 (€ 133,765) Unfavourable step	▼ 34%
Land & buildings	€ 50,872 Land & buildings 2022: € 50,872 First fiscal year in the series	€ 41,741 Land & buildings 2023: € 41,741 ▼ 18% vs 2022 (€ 50,872) Unchanged	€ 33,495 Land & buildings 2024: € 33,495 ▼ 20% vs 2023 (€ 41,741) Unchanged	€ 25,451 Land & buildings 2025: € 25,451 ▼ 24% vs 2024 (€ 33,495) Unchanged	▼ 24%
Retained profit	€ 201,232 Retained profit 2022: € 201,232 First fiscal year in the series	€ 240,492 Retained profit 2023: € 240,492 ▲ 20% vs 2022 (€ 201,232) Favourable step	€ 270,805 Retained profit 2024: € 270,805 ▲ 13% vs 2023 (€ 240,492) Favourable step	€ 281,455 Retained profit 2025: € 281,455 ▲ 4% vs 2024 (€ 270,805) Favourable step	▲ 4%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 50,000 Dividend 2023: € 50,000 Unchanged (€ 0) Unchanged	€ 75,000 Dividend 2024: € 75,000 ▲ 50% vs 2023 (€ 50,000) Unchanged	€ 75,000 Dividend 2025: € 75,000 Unchanged (€ 75,000) Unchanged
Bank debt	€ 5,870 Bank debt 2022: € 5,870 First fiscal year in the series	€ 23,312 Bank debt 2023: € 23,312 ▲ 297% vs 2022 (€ 5,870) Unfavourable step	€ 80,182 Bank debt 2024: € 80,182 ▲ 244% vs 2023 (€ 23,312) Unfavourable step	€ 60,244 Bank debt 2025: € 60,244 ▼ 25% vs 2024 (€ 80,182) Favourable step	▼ 25%
Balance sheet total	€ 436,678 Balance sheet total 2022: € 436,678 First fiscal year in the series	€ 525,669 Balance sheet total 2023: € 525,669 ▲ 20% vs 2022 (€ 436,678) Unchanged	€ 659,034 Balance sheet total 2024: € 659,034 ▲ 25% vs 2023 (€ 525,669) Unchanged	€ 681,585 Balance sheet total 2025: € 681,585 ▲ 3% vs 2024 (€ 659,034) Unchanged	▲ 3%
Employees (FTE)	3.3 Employees (FTE) 2022: 3.3 First fiscal year in the series	1.9 Employees (FTE) 2023: 1.9 ▼ 1.4 vs 2022 (3.3) Unchanged	2.3 Employees (FTE) 2024: 2.3 ▲ 0.4 vs 2023 (1.9) Unchanged	2.3 Employees (FTE) 2025: 2.3 Unchanged (2.3) Unchanged

Key figures of PHARM-OZ, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARM-OZ?

What happened at PHARM-OZ in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 9, 2026 New annual accounts for financial year 2025: profit of € 85,650 (▼ 19% vs 2024). Source: NBB ↗
Jan 1, 1968 Start of the company according to the CBE. KBO
Dec 1, 1967 New establishment in Charleroi. KBO

In short

From € 707 profit in 2022 to € 85,650 profit in 2025.

Paid € 44,943 in corporate taxes since 2022.

Best year ever: 2024, with € 105,313 profit.

On average € 135,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMA OZ 100%

The stake of PHARMA OZ comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARM-OZ

Behind PHARM-OZ are DERYA GEDERET and PHARMA OZ SRL. The shares are held by PHARMA OZ (100%).

Directors

According to the 2025 annual accounts

DERYA GEDERET

Director

PHARMA OZ SRL

Director · represented by MEHMET OZ

Shareholders

PHARMA OZ

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée de Châtelet 40

6060 Charleroi

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0401.670.169

VAT number

BE 0401.670.169

Registered office

Chaussée de Châtelet 40, 6060 Charleroi

Names & denominations

PHARM-OZ

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

1 January 1968

Peppol

Active · Active since 29 Apr 2026

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARM-OZ

Financials

What happened to PHARM-OZ?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions